New study to reveal hidden immune effects of common leukemia drug
NCT ID NCT06992934
First seen Jun 22, 2026 · Last updated Jun 22, 2026
Summary
This study will observe 10 adults with acute myeloid leukemia who are receiving the drug gilteritinib after a stem cell transplant. Researchers want to understand how gilteritinib affects the behavior, metabolism, and function of immune cells like T-cells and monocytes. The goal is to gather information that could help design better ways to prevent cancer relapse after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de NICE
Nice, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gilteritinib
What this could lead to
If successful, this could help doctors understand how to better combine targeted drugs with cell therapies to prevent cancer relapse after transplant.
What could go wrong
This is a very small, early observational study with only 10 participants. It is not designed to test if gilteritinib works, only to explore its effects on immune cells, so results may not lead to direct treatment changes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.